What is HC Wainwright's Forecast for SLN FY2029 Earnings?

Silence Therapeutics plc (NASDAQ:SLN - Free Report) - Research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Silence Therapeutics in a research note issued to investors on Wednesday, January 29th. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of $0.66 for the year. HC Wainwright has a "Buy" rating and a $75.00 price target on the stock. The consensus estimate for Silence Therapeutics' current full-year earnings is ($1.77) per share.

Several other equities research analysts have also recently weighed in on SLN. William Blair restated an "outperform" rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. BMO Capital Markets reissued an "outperform" rating on shares of Silence Therapeutics in a report on Monday, December 2nd. Chardan Capital reaffirmed a "buy" rating and set a $55.00 price objective on shares of Silence Therapeutics in a report on Tuesday, December 10th. Finally, Morgan Stanley reissued an "overweight" rating and issued a $49.00 target price on shares of Silence Therapeutics in a research note on Tuesday, October 8th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Silence Therapeutics presently has an average rating of "Buy" and an average target price of $54.75.

Silence Therapeutics Price Performance

Shares of SLN stock traded up $0.56 during trading hours on Friday, hitting $5.62. 188,399 shares of the company's stock were exchanged, compared to its average volume of 309,144. The stock's 50-day moving average is $6.56 and its 200-day moving average is $13.63. Silence Therapeutics has a 52 week low of $4.82 and a 52 week high of $27.72. The stock has a market cap of $168.20 million, a price-to-earnings ratio of -3.58 and a beta of 1.08.

Institutional Trading of Silence Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Eventide Asset Management LLC bought a new position in Silence Therapeutics during the 3rd quarter worth approximately $11,635,000. Millennium Management LLC raised its holdings in Silence Therapeutics by 91.2% in the second quarter. Millennium Management LLC now owns 782,941 shares of the company's stock worth $14,876,000 after purchasing an additional 373,523 shares during the period. Point72 Asset Management L.P. boosted its position in shares of Silence Therapeutics by 219.3% during the third quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company's stock worth $8,505,000 after purchasing an additional 321,300 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Silence Therapeutics by 32.8% in the 3rd quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company's stock valued at $19,798,000 after buying an additional 268,250 shares during the period. Finally, Parkman Healthcare Partners LLC increased its position in shares of Silence Therapeutics by 71.8% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company's stock valued at $9,051,000 after buying an additional 208,029 shares in the last quarter. Institutional investors own 98.73% of the company's stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.